Your browser is no longer supported. Please, upgrade your browser.
Settings
DMAC DiaMedica Therapeutics Inc. daily Stock Chart
DMAC [NASD]
DiaMedica Therapeutics Inc.
Index- P/E- EPS (ttm)-0.74 Insider Own8.37% Shs Outstand11.96M Perf Week-5.28%
Market Cap40.77M Forward P/E- EPS next Y- Insider Trans- Shs Float8.49M Perf Month-19.76%
Income- PEG- EPS next Q- Inst Own13.72% Short Float0.37% Perf Quarter-10.26%
Sales0.50M P/S81.55 EPS this Y- Inst Trans- Short Ratio0.60 Perf Half Y-56.73%
Book/sh1.42 P/B2.39 EPS next Y- ROA- Target Price- Perf Year-58.11%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.46 - 13.77 Perf YTD17.18%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.46% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.40% ATR0.26
Employees9 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)40.64 Volatility6.25% 6.10%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.19 Prev Close3.41
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume52.36K Price3.38
Recom- SMA20-12.13% SMA50-6.33% SMA200-42.26% Volume6,174 Change-0.88%
Mar-05-19Initiated Lake Street Buy $9
Mar-19-19 04:30PM  DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-18-19 01:56PM  DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call GlobeNewswire
Mar-12-19 01:00PM  DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019 GlobeNewswire
Feb-14-19 08:00AM  DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease GlobeNewswire
Jan-22-19 07:45AM  DiaMedica Therapeutics Announces Publication of a Paper, Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke, in the Journal Therapeutic Advances in Neurological Disorders GlobeNewswire
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire
Jan-10-19 08:27AM  The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits Benzinga
Jan-09-19 05:00PM  DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange GlobeNewswire
Jan-03-19 10:41AM  UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease GlobeNewswire
Dec-02-18 05:01PM  IPO Outlook For The Week: Proteins, Fashion And Finance Benzinga
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.